Questions over Pfizer’s marketing claims resurface as scrutiny grows around blockbuster drug promotion

Pfizer’s Vyndamax (tafamidis) franchise generated worldwide sales of $6.3 billion in 2025, reflecting 17% growth from 2024. This made it one of the company’s most valuable products and the best-selling drug in the ATTR-CM market, writes James Wilson.

In an industry built…